InflaRx Announces Participation in September Investor Conferences

Rhea-AI Summary

InflaRx (NASDAQ:IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced its participation in two major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3-5) with a fireside chat on September 4th at 9:10 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10) with a presentation on September 9th at 3:30 PM ET.

InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, and they are also developing INF904, an oral small molecule C5a receptor inhibitor.

JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows:

Cantor Global Healthcare Conference 2025
September 3 - 5, 2025 in New York, NY
Fireside chat on September 4th at 9:10 AM ET

InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view the fireside chat live stream and its replay is available here.

H.C. Wainwright 27th Annual Global Investment Conference
September 8 - 10, 2025 in New York, NY
Presentation on September 9th at 3:30 PM ET

InflaRx will also conduct one-on-one investor meetings on September 9th. A link to register for the presentation live stream and its replay is available here.

About InflaRx

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies. InflaRx is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

When is InflaRx (IFRX) presenting at the Cantor Global Healthcare Conference 2025?

InflaRx will participate in a fireside chat on September 4th, 2025 at 9:10 AM ET at the Cantor Global Healthcare Conference in New York, NY.

What time is InflaRx's presentation at the H.C. Wainwright Conference 2025?

InflaRx will present on September 9th, 2025 at 3:30 PM ET at the H.C. Wainwright Global Investment Conference in New York, NY.

What are the main products being developed by InflaRx (IFRX)?

InflaRx is developing vilobelimab, an intravenous anti-C5a monoclonal antibody, and INF904, an oral small molecule inhibitor of C5a receptor signaling.

Where can investors access InflaRx's conference presentations?

Live streams and replays of both presentations will be available through links provided by the company for registered participants.

What is InflaRx's therapeutic focus?

InflaRx focuses on anti-inflammatory therapeutics by targeting the complement system, specifically developing inhibitors of the complement activation factor C5a and its receptor.